Effect of anti-angiogenic drugs along with chemotherapy in breast cancer treatment: review article

Document Type : Review Article

Authors

1 M.Sc. of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Assistant professor, Department of Genetic, Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Assistant professor, Department of Genetic, Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Assistant professor, Department of Genetic, Department of Modern Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Assistant professor, Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Professor, Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Introduction: Cancer is one of the most common causes of death in the world and breast cancer is known as the second leading cause of death in women worldwide. Breast cancer is a heterogeneous tumor; various studies have shown that angiogenesis plays an important role in progression and development of cancer. Clinical studies have been performed on the relationship between anti-angiogenic drugs along with chemotherapy in improvement of breast cancer treatment. This review article was performed with aim to evaluate the effect of anti-angiogenic drugs along with chemotherapy in breast cancer treatment.
Methods: In this review study, the related articles were searched in databases of Scopus, PubMed, ISI and Google scholar by the key words including “Breast cancer”, “Anti-angiogenic drug”, ” Chemotherapy” and “Angiogenesis” in Mesh between 2000-2018. No time limitation was considered in selection of the articles. Selection of the articles was based on use of anti-angiogenic drugs along with chemotherapy or as part of chemotherapy drugs in breast cancer treatment. At the end of study, data were analyzed qualitatively.
Results: According to the studies’ results, it was determined that use of anti-angiogenic drugs in improving breast cancer treatment could be more investigated. VEGF and VEGFR inhibitors have shown different clinical effects that could be due to differences in dosage, method of consumption or drug interactions.
Conclusion: Although anti-angiogenic drugs have positive role in improving breast cancer treatment, since different results in doses and method of consumption of these drugs were observed in clinical trials, performing more studies in this regard is required. In general, it seems that these drugs in combination with standard chemotherapy agents could be a good candidate for treatment and increasing survival rate in breast cancer patients.

Keywords

References

  1. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res 2017; 50(1):33.
  2. Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, Maftouh M, et al. The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress. J Cell Biochem 2018; 119(1):213-22.
  3. Bahrami A, Hassanian SM, Khazaei M, Hasanzadeh M, Shahidsales S, Maftouh M, et al. The therapeutic potential of targeting tumor microenvironment in breast cancer: rational strategies and recent progress. J Cell Biochem 2018; 119(1):111-22.
  4. Bahrami A, Khazaei M, Shahidsales S, Hassanian SM, Hasanzadeh M, Maftouh M, et al. The therapeutic potential of PI3K/Akt/mTOR inhibitors in breast cancer: rational and progress. J Cell Biochem 2018; 119(1):213-22.
  5. Yaghmaei S, Bani Hashemi G, Ghorbani R. Survival rate following treatment of primary breast cancer in Semnan, Iran (1991-2002). Koomesh 2008; 9(2):111-6. (Persian).
  6. Seyedfatemi N, Salsali M, Rezaee N, Rahnavard Z. Women’s health concept: a meta-synthesis study. Iran J Public Health 2014; 43(10):1335-44.
  7. Salehi E, Amjadi FS, Khazaei M. Angiogenesis in health and disease: role of vascular endothelial growth factor (VEGF). J Isfahan Med Sch 2011; 29:132. (Persian).
  8. Fam NP, Verma S, Kutryk M, Stewart DJ. Clinician guide to angiogenesis. Circulation 2003; 108(21):2613-8.
  9. Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and breast cancer: Focus on angiogenesis. Int J Mol Sci 2015; 16(5):11728-49.
  10. Douglas D, Nakhuda GS, Sauer MV, Zimmermann RC. Angiogenesis and ovarian function. J Fertil Reprod 2005; 15(4):7-15.
  11. Salter JT, Miller KD. Antiangiogenic agents in breast cancer. Cancer Invest 2007; 25(7):518-26.
  12. Odorisio T, Cianfarani F, Failla CM, Zambruno G. The placenta growth factor in skin angiogenesis. J Dermatol Sci 2006; 41(1):11-9.
  13. Tahergorabi Z, Khazaei M. The relationship between inflammatory markers, angiogenesis, and obesity. ARYA Atheroscler 2013; 9(4):247-53.
  14. Khazaei M, Fallahzadeh AR, Sharifi MR, Afsharmoghaddam N, Javanmard SH, Salehi E. Effects of diabetes on myocardial capillary density and serum angiogenesis biomarkers in male rats. Clinics (Sao Paulo) 2011; 66(8):1419-24.
  15. Nematollahi S, Nematbakhsh M, Haghjooyjavanmard S, Khazaei M, Salehi M. Inducible nitric oxide synthase modulates angiogenesis in ischemic hindlimb of rat. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153(2):125-9.
  16. Bahreyni A, Khazaei M, Rajabian M, Ryzhikov M, Avan A, Hassanian SM. Therapeutic potency of pharmacological adenosine receptor agonist/antagonist in angiogenesis, current status and perspectives. J Pharm Pharmacol 2018; 70(2):191-6.
  17. Fakhrejahani E, Toi M. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Jpn J Clin Oncol 2014; 44(3):197-207.
  18. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013; 14(10):933-42.
  19. Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer 2017; 70:146-55.
  20. Tiainen L, Tanner M, Lahdenperä O, Vihinen P, Jukkola A, Karihtala P, et al. Bevacizumab combined with docetaxel or paclitaxel as first-line treatment of HER2-negative metastatic breast cancer. Anticancer Res 2016; 36(12):6431-8.
  21. Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci 2015; 112(46):14325-30.
  22. Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012; 8(4):403-14.
  23. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009; 6(10):569-79.
  24. Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, et al. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. Breast 2013; 22(5):650-6.
  25. Braga S, Cardoso J, Andre S, Brito M, Sanchez P, Orvalho L, et al. Does hypoxic response mediate primary resistance to sunitinib in untreated locally advanced breast cancer? Curr Cancer Drug Targets 2017; 17(1):62-73.
  26. Toi M, Saeki T, Iwata H, Inoue K, Tokuda Y, Sato Y, et al. A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast Cancer 2014; 21(1):20-7.
  27. Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist 2012; 17(4):536-42.
  28. De Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014; 15(10):1137-46.
  29. Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat 2014; 143(1):141-51.
  30. Chen J, Yao Q, Li D, Zhang J, Wang T, Yu M, et al. Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study. BMC Cancer 2013; 13(1):248.
  31. Chen J, Li D, Yao Q, Zhang J, Wang T, Wang L. Combination of recombinant human endostatin and neoadjuvant chemotherapy for breast cancer. Zhonghua Yi Xue Za Zhi 2012; 92(10):668-71.
  32. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, et al. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer 2012; 12(6):387-91.
  33. Cazzaniga ME, Dionisio MR, Riva F. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett 2017; 400:252-8.
  34. Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett 2015; 358(2):100-6.
  35. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108(2):452-9.
  36. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26(30):4899-905.
  37. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, et al. Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother 2008; 20(5):632-9.
  38. Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006; 6:225.
  39. Wang Z, Lu J, Leaw S, Hong X, Wang J, Shao Z, et al. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 2012; 69(2):515-22.
  40. Alagizy HA, Shehata MA, Hashem TA, Abdelaziz KK, Swiha MM. Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer. Hematol Oncol Stem Cell Ther 2015; 8(1):22-7.
  41. Perroud HA, Alasino CM, Rico MJ, Mainetti LE, Queralt F, Pezzotto SM, et al. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response. Cancer Chemother Pharmacol 2016; 77(2):365-74.
  42. Kummar S, Wade JL, Oza AM, Sullivan D, Chen AP, Gandara DR, et al. Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Invest New Drugs 2016; 34(3):355-63.
  43. Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer 2014; 14(1):820.
  44. Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Invest New Drugs 2013; 31(5):1307-10.
  45. Jia Q, Xu J, Jiang W, Zheng M, Wei M, Chen J, et al. Dynamic contrast-enhanced mr imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer. Int J Med Sci 2013; 10(2):110-8.
  46. Masuda N, Iwata H, Aogi K, Xu Y, Ibrahim A, Gao L, et al. Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study. Jpn J Clin Oncol 2016; 46(12):1088-94.
  47. Tsuji W, Ishiguro H, Tanaka S, Takeuchi M, Ueno T, Toi M. Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. Int J Clin Oncol 2014; 19(3):452-9.
  48. Tan W, Dueck A, Flynn P, Steen P, Anderson D, Rowland K, et al. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol 2013; 24(10):2548-54.
  49. Yoshinami T, Yagi T, Okuno J, Kittaka N, Ishitobi M, Sugimoto N, et al. Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer. Breast Cancer 2017; 24(1):147-51.
  50. Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, et al. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer 2014; 14(1):166.
The Iranian Journal of Obstetrics, Gynecology and Infertility
Volume 22, Issue 5
July 2019
Pages 78-89

Files

Share

How to cite

Statistics